Caspofungin: Difference between revisions
From IDWiki
m (Text replacement - " species]]" to "]]") |
(Liver dosing) |
||
| Line 26: | Line 26: | ||
=== Hepatic Dosing === |
=== Hepatic Dosing === |
||
* Reduce to 35 mg IV daily in cases of moderate hepatic impairment |
* Reduce to 70 mg IV load followed by 35 mg IV daily in cases of moderate or severe hepatic impairment ([[Child-Pugh classification|Child-Pugh class]] B or C) |
||
=== Renal Dosing === |
=== Renal Dosing === |
||
Latest revision as of 15:48, 1 April 2023
Background
- Echinocandin antifungal
Mechanism of Action
- Like all echinocandins, inhibits β-D-glucan synthase
Spectrum of Activity
- Active against Candida, Aspergillus
Pharmacokinetics and Pharmacodynamics
- Only 2% excreted unchanged in the kidney
Dosing
- Caspofungin 70 mg IV over 1 hour followed by 50 mg IV daily
- May be increased to 70 mg daily with cytochrome P450 3A4 inducers such as rifampin, nevirapine, efavirenz, carbamazepine, dexamethasone, and phenytoin
Pediatric Dosing
- Casponfungin 70 mg/m2 IV followed by 50 mg/m2 IV daily
Hepatic Dosing
- Reduce to 70 mg IV load followed by 35 mg IV daily in cases of moderate or severe hepatic impairment (Child-Pugh class B or C)
Renal Dosing
- No specific recommendations
Safety
Adverse Drug Events
- Fevers, chills, phlebitis/thrombophlebitis, tachycardia, nausea, vomiting, rash, abdominal pain, headache, and diarrhea
- Modest liver enzyme elevations
Monitoring
- Liver enzymes
- No specific recommendations
